Fig. 1From: Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practiceEstimated proportions surviving without TD divided by regimen type (log-rank p < 0.001)Back to article page